Hims shares slide after Visa flags payment disputes, but an analyst argues GLP-1 customers are staying

Hims & Hers Health (Hims) took a sharp hit in trading tied to payment disputes, after a market post said Visa flagged disagreements in transactions. The post characterized the move as Hims’s worst day in about a month, reflecting how quickly payment-related headlines can spill into retail investors’ expectations for the online telehealth company.

According to the same post, Visa’s dispute activity could translate into a financial cost for Hims, with an estimated $75,000 surcharge. It also said Visa’s process includes thresholds tied to dispute rates, and that Hims would need to bring its dispute rate below 1.5% to resolve or reduce the flagged issues.

Visa dispute programs are designed to identify merchant behavior that increases the likelihood of customer chargebacks or payment reversals. When dispute rates rise, the card network or payment processor can impose additional requirements or costs on the merchant. While the post did not provide detailed mechanics, the key point for Hims is that payment performance can become a direct line-item risk, not just a customer-service metric.

Beyond the dispute-related concern, the post included an opposing argument from an analyst about customer stability. The analyst reportedly said that users of GLP-1-related offerings are “sticking around,” implying that even if there is near-term friction in payments, underlying demand for weight-loss medications and related services may not be collapsing.

GLP-1 refers to a class of drugs used for weight loss and diabetes, and companies in digital health have increasingly built programs around patient intake, ongoing medication management, and fulfillment. In the post’s framing, the durability of those customers matters because churn and retention directly affect subscription revenue and future ordering behavior, which can help offset operational costs.

Still, the dispute episode highlights how second-order risks can surface for online merchants that rely on frequent payments. If Visa-driven monitoring leads to surcharges or operational changes, those costs could compress margins at the same time that competition in telehealth and medication delivery remains intense.

The market post did not disclose whether Hims has already taken steps to reduce disputes, nor did it specify the time horizon for meeting the 1.5% dispute-rate target. It also did not lay out the underlying dispute categories, such as billing disputes versus fulfillment or customer dissatisfaction, which limits how much can be inferred about the root cause.

Investors may look next for whether Hims provides additional detail in a filing, earnings communication, or investor update about Visa-related monitoring and any plan to reduce disputes. The most immediate announcement would be evidence of improved dispute metrics over time and commentary on whether GLP-1 retention assumptions hold up in reported patient and revenue trends. Separate but related, investors may also watch for any changes in payment processing, customer communications, or program terms that could reduce the number of contested transactions.